



Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Albert L. Ferro*
Donald R. Banowitz
Peter A. Jackman
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Eldora Ellison Floyd
Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes

Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhullier
Rae Lynn Pongaman
George S. Bardmesser
Daniel A. Klein*
Jason D. Eisenberg
Michael D. Specht
Andrea J. Kamage
Tracy L. Muller*
LuAnne M. DeSantis
Ann E. Summerfield
Tiera S. Coston
Aric W. Ledford*
Helene C. Carlson
Timothy A. Doyle*
Jessica L. Parezo
Gaby L. Longworth*

Lori A. Gordon*
Nicole D. Dretar*
Ted J. Ebersole
Jyoti C. Iyer*
Laura A. Vogel

Registered Patent Agents*
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Aaron L. Schwartz
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Jeffrey S. Lundgren
Victoria S. Rutherford
Michelle K. Holoubek

Robert H. DeSelms
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse
Michael G. Penn
Christopher J. Walsh

Of Counsel
Kenneth C. Bass III
Evan R. Smith
Marvin C. Guthrie

*Admitted only in Maryland
*Admitted only in Virginia
*Practice Limited to
Federal Agencies

July 27, 2004

WRITER'S DIRECT NUMBER:
(202) 772-8615

INTERNET ADDRESS:
FRANKC@SKGF.COM

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Art Unit 1615

Re: U.S. Utility Patent Application
Application No. 09/972,913; Filed: October 10, 2001
For: **Use of Clloquinol for the Therapy of Alzheimer's Disease**
Inventors: BUSH *et al.*
Our Ref: 0609.4540003/TJS/FRC

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Fee Transmittal Form (PTO/SB/17);
2. Information Disclosure Statement;
3. Listing of the cited documents on Form PTO-1449 (55 sheets);
4. A copy of five (5) of the cited documents on Form PTO-1449;
5. Credit Card Payment Form (PTO-2038) in the amount of **\$180.00** to cover the IDS fee; and
6. Return postcard.


It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents
July 27, 2004
Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham
Attorney for Applicants
Registration No. 50,437

FRC/pcd
Encls.

291690v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Complete if Known

Application Number 09/972,913
 Filing Date October 10, 2003
 First Named Inventor Ashley I. BUSH
 Examiner Name Sheikh, H.
 Art Unit 1615
 Attorney Docket No. 0609.4540003/TJS/FRC

JUL 27 2004

METHOD OF PAYMENT (check all that apply)

☐ Check ☒ Credit card ☐ Money Order ☒ Other** ☐ None

☐ **Charge any deficiencies or credit any overpayments in the fees to Deposit Acct. No. 19-0036.

 Deposit Account Number 19-0036
 Deposit Account Name Sterne, Kessler, Goldstein & Fox P.L.L.C.

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments☒ Charge any additional fee(s) or any underpayment of fee(s)☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	
SUBTOTAL (1) (\$)			

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	- 20 ** =	X	
Multiple Dependent	- 3 ** =	X	

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for <i>ex parte</i> reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	180.00
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

180.00

SUBMITTED BY

(Complete if applicable)

Name (Print/Type) Frank R. Cottingham Registration No. 50.437 Telephone (202) 371-2600
 Signature Date July 27, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
 SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Bush *et al.*

Appl. No. 09/972,913

Filed: October 10, 2001

For: **Use of Clioquinol for the
Therapy of Alzheimer's Disease**



Confirmation No. 5681

Art Unit: 1615

Examiner: Sheikh, H.

Atty. Docket: 0609.4540003/TJS/FRC

Information Disclosure Statement

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450
Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents AF1, AG1, AH1, AI1 and AJ1 are submitted herewith. Copies of all other documents were cited by or submitted to the Office in an IDS that complies with 37 C.F.R. § 1.98(a)-(c) in Application No. 09/224,953, Bush *et al.*, filed January 4, 1999, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.


This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application. Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Frank R. Cottingham
Attorney for Applicants
Registration No. 50,437

Date: July 27, 2004
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4540003/TJS/FRC
FIRST NAMED INVENTOR
Bush *et al.*
FILING DATE
October 10, 2001

APPLICATION NO.
09/972,913
ART UNIT
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1	5,373,021	12/13/1994	Marangos			04/26/1993
	AB1	5,688,516	11/18/1997	Raad <i>et al.</i>			10/03/1994
	AC1	5,688,651	11/18/1997	Solomon			12/16/1994
	AD1	5,705,401	01/06/1998	Masters <i>et al.</i>			09/16/1994
	AE1	5,721,106	02/24/1998	Maggio <i>et al.</i>			09/12/1994
	AF1	5,980,914	11/09/1999	Gerolymatos			02/13/1998
	AG1	5,994,323	11/30/1999	Gerolymatos			02/13/1998
	AH1	6,001,852	12/14/1999	Gerolymatos			02/13/1998
	AI1	6,323,218	11/27/2001	Bush <i>et al.</i>			03/11/1998
	AJ1	2002/0082273	06/27/2002	Bush <i>et al.</i>			09/21/2001
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1	WO 92/18111	10/29/1992	WIPO			Yes No
	AM1	WO 93/10459	05/27/1993	WIPO			Yes No
	AN1	WO 93/24451	12/09/1993	WIPO			Yes No
	AO1	WO 94/04167	03/03/1994	WIPO			Yes No
	AP1	WO 95/31199	11/23/1995	WIPO			Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Assaf, S.Y., and Chung, S-H., "Release of endogenous Zn ²⁺ from brain tissue during activity," <i>Nature</i> 308:734-736, Nature Publishing Group (April 1984)
	AS	1	Atwood, C.S., <i>et al.</i> , "Dramatic Aggregation of Alzheimer A β by Cu(II) Is Induced by Conditions Representing Physiological Acidosis," <i>J. Biol. Chem.</i> 273:12817-12826, American Society for Biochemistry and Molecular Biology (May 1998)
	AT	1	Bacon, P.A., <i>et al.</i> , "Rheumatoid Disease, Amyloidosis and its Treatment with Penicillamine," <i>Eur. J. Rheum. Inflamm.</i> 2:70-74, Cameron Publishers (1979)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4540003/TJS/FRCAPPLICATION NO.
09/972,913FIRST NAMED INVENTOR
Bush *et al.*FILING DATE
October 10, 2001ART UNIT
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2	WO 96/07096	03/07/1996	WIPO			Yes No
	AM2	WO 96/12544	05/02/1996	WIPO			Yes No
	AN2	WO 96/28471	09/19/1996	WIPO			Yes No
	AO2	WO 97/04794	02/13/1997	WIPO			Yes No
	AP2	WO 97/09976	03/20/1997	WIPO			Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>2</u>	Barrow, C.J., and Zagorski, M.G., "Solution Structures of β Peptide and Its Constituent Fragments: Relation to Amyloid Deposition," <i>Science</i> 253:179-182, American Association for the Advancement of Science (July 1991)
	AS	<u>2</u>	Barrow, C.J., <i>et al.</i> , "Solution Conformations and Aggregational Properties of Synthetic Amyloid β -Peptides of Alzheimer's Disease," <i>J. Mol. Biol.</i> 225:1075-1093, Academic Press (June 1992)
	AT	<u>2</u>	Basun, H., <i>et al.</i> , "Metals and trace elements in plasma and cerebrospinal fluid in normal ageing and Alzheimer's disease," <i>J. Neural Transm. [P-D Sect.]</i> 3:231-258, Springer-Verlag (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


<div style="text-align: center;">  <p>FORM PTO-1449</p> <p>INFORMATION DISCLOSURE STATEMENT</p> </div>	ATTY. DOCKET NO. 0609.4540003/TJS/FRC	APPLICATION NO. 09/972,913
	FIRST NAMED INVENTOR Bush <i>et al.</i>	
	FILING DATE October 10, 2001	ART UNIT 1615

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL3	WO 97/36885	10/09/1997	WIPO			Yes No
	AM3	WO 98/06403	02/19/1998	WIPO			Yes No
	AN3	WO 98/40071	09/17/1998	WIPO			Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>3</u>	Behl, C., <i>et al.</i> , "Hydrogen Peroxide Mediates Amyloid β Protein Toxicity," <i>Cell</i> 77:817-827, Cell Press (June 1994)
	AS	<u>3</u>	Biaglow, J.E., and Kachur, A.V., "The Generation of Hydroxyl Radicals in the Reaction of Molecular Oxygen with Polyphosphate Complexes of Ferrous Ion," <i>Radiat. Res.</i> 148:181-187, Kluge Carden Jennings Pub. Co. (August 1997)
	AT	<u>3</u>	Boado, R.J., <i>et al.</i> , "Drug Delivery of Antisense Molecules to the Brain for Treatment of Alzheimer's Disease and Cerebral AIDS," <i>J. Pharm. Sci.</i> 87:1308-1315, American Pharmaceutical Association (November 1998)

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>	



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 0609.4540003/TJS/FRC		APPLICATION NO. 09/972,913
FIRST NAMED INVENTOR Bush <i>et al.</i>		
FILING DATE October 10, 2001	ART UNIT 1615	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS


EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>4</u>	Borman, S., "Diverse Strategies Emerge For Diagnosing Alzheimer's Disease," <i>Chem. Eng. News</i> 272:33-34, American Chemical Society (June 1996)
	AS	<u>4</u>	Bruce, A.J., <i>et al.</i> , " β -Amyloid toxicity in organotypic hippocampal cultures: Protection by EUK-8, a synthetic catalytic free radical scavenger," <i>Proc. Natl. Acad. Sci. USA</i> 93:2312-2316, National Academy of Sciences (March 1996)
	AT	<u>4</u>	Burdick, D., <i>et al.</i> , "Assembly and Aggregation Properties of Synthetic Alzheimer's A4/ β Amyloid Peptide Analogs," <i>J. Biol. Chem.</i> 267:546-554, American Society for Biochemistry and Molecular Biology (January 1992)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


 FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		Page 5 of 55		
		ATTY. DOCKET NO. 0609.4540003/TJS/FRC		APPLICATION NO. 09/972,913
		FIRST NAMED INVENTOR Bush <i>et al.</i>		
		FILING DATE October 10, 2001	ART UNIT 1615	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>5</u>	Burns, J.A., <i>et al.</i> , "Selective Reduction of Disulfides by Tris(2-carboxyethyl)phosphine," <i>J. Org. Chem.</i> 56:2648-2650, American Chemical Society (April 1991)
	AS	<u>5</u>	Busciglio, J., and Yankner, B.A., "Apoptosis and increased generation of reactive oxygen species in Down's Syndrome neurons <i>in vitro</i> ," <i>Nature</i> 378:776-779, Nature Publishing Co. (December 1995)
	AT	<u>5</u>	Bush, A.I., <i>et al.</i> , "A Novel Zinc(II) Binding Site Modulates the Function of the β A4 Amyloid Protein Precursor of Alzheimer's Disease," <i>J. Biol. Chem.</i> 268:16109-16112, American Society for Biochemistry and Molecular Biology (August 1993)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	


 <p>FORM PTO-1449</p> <p>INFORMATION DISCLOSURE STATEMENT</p>		Page 6 of 55		
		ATTY. DOCKET NO. 0609.4540003/TJS/FRC		APPLICATION NO. 09/972,913
		FIRST NAMED INVENTOR Bush <i>et al.</i>		
		FILING DATE October 10, 2001	ART UNIT 1615	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>6</u>	Bush, A.I., <i>et al.</i> , "Modulation of A β Adhesiveness and Secretase Site Cleavage by Zinc," <i>J. Biol. Chem.</i> 269:12152-12158, American Society for Biochemistry and Molecular Biology (April 1994)
	AS	<u>6</u>	Bush, A.I., <i>et al.</i> , "The Amyloid β -Protein Precursor and Its Mammalian Homologues," <i>J. Biol. Chem.</i> 269:26618-26621, American Society for Biochemistry and Molecular Biology (October 1994)
	AT	<u>6</u>	Bush, A.I., <i>et al.</i> , "Rapid Induction of Alzheimer A β Amyloid Formation by Zinc," <i>Science</i> 265:1464-1467, American Association for the Advancement of Science (September 1994)

EXAMINER	DATE CONSIDERED
<p>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>	



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	1	Bush, A.I., <i>et al.</i> , Response to "Zinc and Alzheimer's Disease," <i>Science</i> 268:1920-1923, American Association for the Advancement of Science (June 1995)
	AS	1	Butterfield, D.A., <i>et al.</i> , " β -Amyloid Peptide Free Radical Fragments Initiate Synaptosomal Lipoperoxidation in a Sequence-Specific Fashion: Implications to Alzheimer's Disease," <i>Biochem. Biophys. Res. Commun.</i> 200:710-715, Academic Press (April 1994)
	AT	1	Butterfield, D.A., <i>et al.</i> , " $A\beta$ (25-35) Peptide Displays H_2O_2 -Like Reactivity Towards Aqueous Fe^{2+} , Nitroxide Spin Probes, and Synaptosomal Membrane Proteins," <i>Life Sci.</i> 58:217-228, Pergamon Press (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	§	Cherny, R.A., <i>et al.</i> , "The Aggregation of A β in Human Brain is Mediated by Zinc," <i>Abstr. Soc. Neurosci.</i> 23:534, Society For Neuroscience (October 1997)
	AS	§	Chong, Y.-H., and Suh, Y.-H., "Aggregation of amyloid precursor proteins by aluminum in vitro," <i>Brain Research</i> 670:137-141, Elsevier/North-Holland Biomedical Press (January 1995)
	AT	§	Colaco, C.A.L.S., <i>et al.</i> , "The role of the Maillard reaction in other pathologies: Alzheimer's disease," <i>Nephrol. Dial. Transplant.</i> 11(Suppl. 5):7-12, Springer International (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4540003/TJS/FRC
FIRST NAMED INVENTOR
Bush *et al.*
FILING DATE
October 10, 2001

APPLICATION NO.
09/972,913
ART UNIT
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	2	Connor, J.R., <i>et al.</i> , "A Histochemical Study of Iron, Transferrin, and Ferritin in Alzheimer's Diseased Brains," <i>J. Neurosci. Res.</i> 31:75-83, Wiley Interscience (January 1992)
	AS	2	Connor, J.R., <i>et al.</i> , "Ceruloplasmin levels in the human superior temporal gyrus in aging and Alzheimer's disease," <i>Neurosci. Lett.</i> 159:88-90, Elsevier/North-Holland (September 1993)
	AT	2	Coyle, J.T., and Puttfarcken, P., "Oxidative Stress, Glutamate, and Neurodegenerative Disorders," <i>Science</i> 262:689-695, American Association for the Advancement of Science (October 1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4540003/TJS/FRCAPPLICATION NO.
09/972,913FIRST NAMED INVENTOR
Bush *et al.*FILING DATE
October 10, 2001ART UNIT
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	10	Crapper McLachlan, D.R., <i>et al.</i> , "Intramuscular desferrioxamine in patients with Alzheimer's disease," <i>Lancet</i> 337:1304-1308, Lancet Publishing Group (June 1991)
	AS	10	Cuajungco, M.P., and Lees, G.J., "Zinc and Alzheimer's disease: is there a direct link?" <i>Brain Res. Rev.</i> 23:219-236, Elsevier Science B.V. (April 1997)
	AT	10	Dedman, D.J., <i>et al.</i> , "Iron and aluminum in relation to brain ferritin in normal individuals and Alzheimer's-disease and chronic renal-dialysis patients," <i>Biochem J.</i> 287:509-514, UK Biochemical Society (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>11</u>	Deibel, M.A., <i>et al.</i> , "Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: possible relation to oxidative stress," <i>J. Neurol. Sci.</i> 143:137-142, Elsevier (November 1996)
	AS	<u>11</u>	Doré, S., <i>et al.</i> , "Insulin-like growth factor I protects and rescues hippocampal neurons against β -amyloid- and human amylin-induced toxicity," <i>Proc. Natl. Acad. Sci. USA</i> 94:4772-4777, National Academy of Sciences (April 1997)
	AT	<u>11</u>	Dryks, T., <i>et al.</i> , "Amyloidogenicity of β A4 and β A4-bearing Amyloid Protein Precursor Fragments by Metal-catalyzed Oxidation," <i>J. Biol. Chem.</i> 267:18210-18217, American Society for Biochemistry and Molecular Biology (September 1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	Ehmann W.D., <i>et al.</i> , "Brain Trace Elements in Alzheimer's Disease," <i>NeuroToxicology</i> 7:197-206, Elsevier Science (1986)
	AS	<u>12</u>	Esler, W.P., <i>et al.</i> , "Zinc-Induced Aggregation of Human and Rat β -Amyloid Peptides In Vitro," <i>J. Neurochem.</i> 66:723-732, Blackwell Science (February 1996)
	AT	<u>12</u>	Esler, W.P., <i>et al.</i> , "A β deposition inhibitor screen using synthetic amyloid," <i>Nat. Biotechnol.</i> 15:258-263, Nature Publishing Co. (March 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.


<div style="display: flex; align-items: center; justify-content: center;"> <div style="text-align: center;">  </div> <div style="margin-left: 20px;"> FORM PTO-1449 PATENT INFORMATION DISCLOSURE STATEMENT </div> </div>		Page 13 of 55		
		ATTY. DOCKET NO. 0609.4540003/TJS/FRC		APPLICATION NO. 09/972,913
		FIRST NAMED INVENTOR Bush <i>et al.</i>		
		FILING DATE October 10, 2001	ART UNIT 1615	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR	<u>13</u>	Fitzgerald, D.J., "Zinc and Alzheimer's Disease," <i>Science</i> 268:1920, American Association for the Advancement of Science (June 1995)
	AS	<u>13</u>	Fraser, P.E., <i>et al.</i> , "pH-dependent structural transitions of Alzheimer amyloid peptides," <i>Biophys. J.</i> 60:1190-1201, Rockefeller University Press (November 1991)
	AT	<u>13</u>	Frederikse, P.H., <i>et al.</i> , "Oxidative Stress Increases Production of β -Amyloid Precursor Protein and β -Amyloid ($A\beta$) in Mammalian Lenses, and $A\beta$ Has Toxic Effects on Lens Epithelial Cells," <i>J. Biol. Chem.</i> 271:10169-10174, American Society for Biochemistry and Molecular Biology (April 1996)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4540003/TJS/FRC
FIRST NAMED INVENTOR
Bush *et al.*
FILING DATE
October 10, 2001

APPLICATION NO.
09/972,913
ART UNIT
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>14</u>	Frederickson, C.J., "Neurobiology of Zinc and Zinc-Containing Neurons," <i>Int. Rev. Neurobiol.</i> 31:145-238, Academic Press (1989)
	AS	<u>14</u>	Frieden, E., "Ceruloplasmin: A Multi-functional Cupro-protein of Vertebrate Plasma," in <i>Inflammatory Diseases and Copper</i> , Sorenson, J.R.J., ed., Humana Press, Clifton, N.J., pp.159-169 (1982)
	AT	<u>14</u>	Giampaolo, V., "Copper and Inflammation," in: <i>Inflammatory Diseases and Copper</i> , Sorenson, J.R.J., ed., Humana Press, Clifton, N.J., pp. 329-345 (1982)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>15</u>	Giulian, D., <i>et al.</i> , "Specific Domains of β -Amyloid from Alzheimer Plaque Elicit Neuron Killing in Human Microglia," <i>J. Neurosci.</i> 16:6021-6037, Society for Neuroscience (October 1996)
	AS	<u>15</u>	Glenner, G.G., and Wong, C.W., "Alzheimer's Disease: Initial Report of the Purification and Characterization of Novel Cerebrovascular Amyloid Protein," <i>Biochem. Biophys. Res. Commun.</i> 120: 885-890, Academic Press (May 1984)
	AT	<u>15</u>	Golde, T.E., <i>et al.</i> , "Processing of the Amyloid Protein Precursor to Potentially Amyloidogenic Derivatives," <i>Science</i> 255:728-730, American Association for the Advancement of Science (February 1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OTPE
JUL 27 2004
PATENT & TRADEMARK OFFICE

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>16</u>	Good, P.F., <i>et al.</i> , "Selective Accumulation of Aluminum and Iron in the Neurofibrillary Tangles of Alzheimer's Disease: A Laser Microprobe (LAMMA) Study," <i>Ann. Neurol.</i> 31:286-292, Wiley-Liss (March 1992)
	AS	<u>16</u>	Goodman, Y., <i>et al.</i> , "Nordihydroguaiaretic acid protects hippocampal neurons against amyloid β -peptide toxicity, and attenuates free radical and calcium accumulation," <i>Brain Res.</i> 654:171-176, Elsevier/North-Holland (August 1994)
	AT	<u>16</u>	Goodman, Y., and Mattson, M.P., "Secreted Forms of β -Amyloid Precursor Protein Protect Hippocampal Neurons against Amyloid β -Peptide-Induced Oxidative Injury," <i>Exp. Neurol.</i> 128:1-12, Academic Press (July 1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>17</u>	Gorevic, P.D., <i>et al.</i> , "The Biological Significance of Amyloid," <i>Ann. NY Acad. Sci.</i> 389:380-394, New York Academy Of Sciences (1982)
	AS	<u>17</u>	Grundke-Iqbal, I., <i>et al.</i> , "Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia," <i>Acta Neuropathol.</i> 81:105-110, Springer Verlag (December 1990)
	AT	<u>17</u>	Gutteridge, J.M.C., and Wilkins, S., "Copper Salt-Dependent Hydroxyl Radical Formation Damage to Proteins Acting as Antioxidants," <i>Biochim. Biophys. Acta</i> 759:38-41, Elsevier (August 1983)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>18</u>	Haass, C., <i>et al.</i> , "Amyloid β -peptide is produced by cultured cells during normal metabolism," <i>Nature</i> 359:322-325, Nature Pub. Co. (September 1992)
	AS	<u>18</u>	Haley, J.V., "Zinc Sulfate and Wound Healing," <i>J. Surg. Res.</i> 27:168-174, Academic Press (September 1979)
	AT	<u>18</u>	Halliwell, B., and Gutteridge, J.M.C., "Oxygen toxicity, oxygen radicals, transition metals and disease," <i>Biochem. J.</i> 219:1-14, UK Biochemical Society (April 1984)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>19</u>	Halliwell, B., "Reactive Oxygen Species and the Central Nervous System," <i>J. Neurochem.</i> 59:1609-1623, Blackwell Science (November 1992)
	AS	<u>19</u>	Han, J., <i>et al.</i> , "Quantitation of Hydrogen Peroxide Using Tris(2-carboxyethyl)phosphine," <i>Anal. Biochem.</i> 234:107-109, Academic Press (February 1996)
	AT	<u>19</u>	Han, J.C., and Han, G.Y., "A Procedure for Quantitative Determination of Tris(2-carboxyethyl)phosphine, an Odorless Reducing Agent More Stable and Effective Than Dithiothreitol," <i>Anal. Biochem.</i> 220:5-10, Academic Press (July 1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

PATENT INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>20</u>	Hansen, M.B., <i>et al.</i> , "Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill," <i>J. Immunol. Meth.</i> 119:203-210, North-Holland Pub. Co. (May 1989)
	AS	<u>20</u>	Harman, D., "Aging: A Theory Based on Free Radical and Radiation Chemistry," <i>J. Gerontol.</i> 2:298-300, Gerontological Society Of America (July 1956)
	AT	<u>20</u>	Harris, M.E., <i>et al.</i> , "Direct Evidence of Oxidative Injury Produced by the Alzheimer's β -Amyloid Peptide (1-40) in Cultured Hippocampal Neurons," <i>Exp. Neurol.</i> 131:193-202, Academic Press (February 1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4540003/TJS/FRC
FIRST NAMED INVENTOR
Bush *et al.*
FILING DATE
October 10, 2001

APPLICATION NO.
09/972,913
ART UNIT
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>21</u>	Hensley, K., <i>et al.</i> , "A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 91:3270-3274, National Academy of Sciences (April 1994)
	AS	<u>21</u>	Hensley, K., <i>et al.</i> , "Brain Regional Correspondence Between Alzheimer's Disease Histopathology and Biomarkers of Protein Oxidation," <i>J. Neurochem.</i> 65:2146-2156, Blackwell Science (November 1995)
	AT	<u>21</u>	Hensley, K., <i>et al.</i> , "Reactive Oxygen Species as Causal Agents in the Neurotoxicity of the Alzheimer's Disease-Associated Amyloid Beta Peptide," <i>Ann. NY Acad. Sci.</i> 786:120-134, New York Academy Of Sciences (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE
 JUL 27 2004
 PATENT & INFORMATION

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>22</u>	Hesse, L., <i>et al.</i> , "The β A4 amyloid precursor protein binding to copper," <i>FEBS Lett.</i> 349:109-116, Elsevier Science B.V. (July 1994)
	AS	<u>22</u>	Hilbich, C., <i>et al.</i> , "Aggregation and Secondary Structure of Synthetic Amyloid β A4 Peptides of Alzheimer's Disease," <i>J. Mol. Biol.</i> 218:149-163, Academic Press (March 1991)
	AT	<u>22</u>	Hilbich, C., <i>et al.</i> , "Substitutions of Hydrophobic Amino Acids Reduce the Amyloidogenicity of Alzheimer's Disease β A4 Peptides," <i>J. Mol. Biol.</i> 228:460-473, Academic Press (November 1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>23</u>	Hsu, J.M., <i>et al.</i> , "Zinc Deficiency and Incorporation of ¹⁴ C-labeled Methionine into Tissue Proteins in Rats," <i>J. Nutr.</i> 99:425-432, American Institute Of Nutrition (December 1969)
	AS	<u>23</u>	Huang, X., <i>et al.</i> , "Zinc-induced Alzheimer's A β 1-40 Aggregation Is Mediated by Conformational Factors," <i>J. Biol. Chem.</i> 272:26464-26470, American Society for Biochemistry and Molecular Biology (October 1997)
	AT	<u>23</u>	Ida, N., <i>et al.</i> , "Analysis of Heterogeneous β A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <i>J. Biol. Chem.</i> 271:22908-22914, American Society for Biochemistry and Molecular Biology (September 1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO. 0609.4540003/TJS/FRC		APPLICATION NO. 09/972,913
FIRST NAMED INVENTOR Bush <i>et al.</i>		
FILING DATE October 10, 2001	ART UNIT 1615	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>24</u>	Jarrett, J.T., <i>et al.</i> , "The Carboxy Terminus of the β Amyloid Protein Is Critical for the Seeding of Amyloid Formation: Implications for the Pathogenesis of Alzheimer's Disease," <i>Biochemistry</i> . 32:4693-4697, American Chemical Society (May 1993)
	AS	<u>24</u>	Jarrett, J.T., and Lansbury, Jr., P.T., "Amyloid Fibril Formation Requires a Chemically Discriminating Nucleation Event: Studies of an Amyloidogenic Sequence from the Bacterial Protein OsmB," <i>Biochemistry</i> 31:12345-12352, American Chemical Society (December 1992)
	AT	<u>24</u>	Johnstone, E.M., <i>et al.</i> , "Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis," <i>Brain Res. Mol. Brain Res.</i> 10:299-305, Elsevier Science Publishers (July 1991)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>25</u>	Joshi, J.G., "Iron and Aluminum Homeostasis in Neural Disorders," <i>Environ. Health Persp.</i> 102:207-213, National Institute of Environmental Health Sciences (1994)
	AS	<u>25</u>	Kang, J., <i>et al.</i> , "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor," <i>Nature</i> 325:733-736, Nature Pub. Co. (February 1987)
	AT	<u>25</u>	Kawahara, M., <i>et al.</i> , "Alzheimer's Disease Amyloid β -Protein Forms Zn^{2+} -Sensitive, Cation-Selective Channels Across Excised Membrane Patches from Hypothalamic Neurons," <i>Biophys. J.</i> 73:67-75, Rockefeller University Press (July 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>26</u>	Kennard, M.L., <i>et al.</i> , "Serum levels of the iron binding protein p97 are elevated in Alzheimer's disease," <i>Nat. Med.</i> 2:1230-1235, Nature Pub. Co. (November 1996)
	AS	<u>26</u>	Kidani, Y., <i>et al.</i> , "Mass spectrometry of 5-chloro-7-iodo-8-quinolinol metal chelates," <i>Jpn. Analyst</i> 23:1375-1378 (1974)
	AT	<u>26</u>	Kirschner, D.A., <i>et al.</i> , "Synthetic peptide homologous to β protein from Alzheimer disease forms amyloid-like fibrils <i>in vitro</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 84:6953-6957, National Academy of Sciences (October 1987)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>27</u>	Kirshenbaum, K., and Daggett, V., "pH-Dependent Conformations of the Amyloid β (1-28) Peptide Fragment Explored Using Molecular Dynamics," <i>Biochemistry</i> 34:7629-7639, American Chemical Society (June 1995)
	AS	<u>27</u>	Kisilevsky, R., "Inflammation-Associated Amyloidogenesis," <i>Mol. Neurobiol.</i> 8:65-66, Humana Press (February 1994)
	AT	<u>27</u>	Koh, J.Y., and Choi, D.W., "Quantitative determination of glutamate mediated cortical neuronal injury in cell culture by lactate dehydrogenase efflux assay," <i>J. Neurosci. Meth.</i> 20:83-90, Elsevier Science (May 1987)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>28</u>	Kotaki, H., <i>et al.</i> , "Intestinal Absorption and Metabolism of Clioquinol in the Rat," <i>J. Pharmacobiodyn.</i> 6:881-887, Pharmaceutical Society Of Japan (November 1983)
	AS	<u>28</u>	Kuo, Y-M., <i>et al.</i> , "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <i>J. Biol. Chem.</i> 271:4077-4081, American Society for Biochemistry and Molecular Biology (February 1996)
	AT	<u>28</u>	Landers, J.W., and Zak, B., "Determination of Serum Copper and Iron in a Single Small Sample," <i>Am. J. Clin. Pathol.</i> 29:590-592, American Society of Clinical Pathologists (June 1958)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>29</u>	Lindeman, R.D., <i>et al.</i> , "Myocardial zinc metabolism in experimental myocardial infarction," <i>J. Lab. Clin. Med.</i> 81:194-204, Mosby-Year Book (February 1973)
	AS	<u>29</u>	Linert, W., <i>et al.</i> , "Dopamine, 6-hydroxydopamine, iron, and dioxygen- their mutual interaction and possible implication in the development of Parkinson's disease," <i>Biochim. Biophys. Acta</i> 1316:160-168, Elsevier (1996)
	AT	<u>29</u>	Lockhart, B.P., <i>et al.</i> , "Inhibitors of free radical formation fail to attenuate direct beta-amyloid ₂₅₋₃₅ peptide-mediated neurotoxicity in rat hippocampal cultures," <i>J. Neurosci. Res.</i> 39:494-505, Wiley Interscience (November 1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>30</u>	Lohr, J.B., "Oxygen Radicals and Neuropsychiatric Illness," <i>Arch. Gen. Psychiatry</i> 48:1097-1106, American Medical Association (December 1991)
	AS	<u>30</u>	Maggio, J.E., <i>et al.</i> , "Zinc and Alzheimer's Disease," <i>Science</i> 268:1920-1921, American Association for the Advancement of Science (June 1995)
	AT	<u>30</u>	Mantyh, P.W., <i>et al.</i> , "Aluminum, Iron, and Zinc Ions Promote Aggregation of Physiological Concentrations of β -Amyloid Peptide," <i>J. Neurochem.</i> 61:1171-1174, Blackwell Science (September 1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIPE JC
 JUL 27 2004
 PATENT & TRADEMARK

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>31</u>	Markesbery, W.R., "Oxidative Stress Hypothesis in Alzheimer's Disease," <i>Free Radic. Biol. Med.</i> 23:134-147, Elsevier Science (1997)
	AS	<u>31</u>	Masters, C.L., <i>et al.</i> , "Amyloid plaque core protein in Alzheimer disease and Down syndrome," <i>Proc. Natl. Acad. Sci. USA</i> 82:4245-4249, National Academy of Sciences (June 1985)
	AT	<u>31</u>	Masters, C.L., <i>et al.</i> , "Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels," <i>EMBO J.</i> 4:2757-2763, Oxford University Press (November 1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>32</u>	Maury, C.P.J., "Biology of Disease: Molecular Pathogenesis of β -Amyloidosis in Alzheimer's Disease And Other Cerebral Amyloidoses," <i>Lab. Invest.</i> 72:4-16, Lippincott Williams & Wilkins (January 1995)
	AS	<u>32</u>	McGeer, P.L., and McGeer, E.G., "The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases," <i>Brain Res. Rev.</i> 21:195-218, Elsevier Science B.V (September 1995)
	AT	<u>32</u>	Mecocci, P., <i>et al.</i> , "Oxidative Damage to Mitochondrial DNA Shows Marked Age-dependent Increases in Human Brain," <i>Ann. Neurol.</i> 34:609-616, Wiley-Liss (October 1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4540003/TJS/FRC
FIRST NAMED INVENTOR
Bush *et al.*
FILING DATE
October 10, 2001

APPLICATION NO.
09/972,913
ART UNIT
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>33</u>	Menkin, V., "Studies on Inflammation. X. The Cytological Picture of an Inflammatory Exudate in Relation to its Hydrogen Ion Concentration," <i>Am. J. Pathol.</i> 10:193-210, American Society for Investigative Pathology (March 1934)
	AS	<u>33</u>	Michikawa, M., et al., "Oxygen Radical-Induced Neurotoxicity in Spinal Cord Neuron Cultures," <i>J. Neurosci. Res.</i> 37:62-70, Wiley Interscience (January 1994)
	AT	<u>33</u>	Milanino, R., et al., "Copper and the Inflammatory Process," <i>Advances in Inflammation Research</i> 1:281-291, Raven Press (1979)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>34</u>	Moir, R.D., <i>et al.</i> , "Relative Increase in Alzheimer's Disease of Soluble Forms of Cerebral A β Amyloid Protein Precursor Containing the Kunitz Protease Inhibitory Domain," <i>J. Biol. Chem.</i> 273:5013-5019, American Society for Biochemistry and Molecular Biology (February 1998)
	AS	<u>34</u>	Mok, S.S., <i>et al.</i> , "A Novel Metalloprotease in Rat Brain Cleaves the Amyloid Precursor Protein of Alzheimer's Disease Generating Amyloidogenic Fragments," <i>Biochemistry</i> 36:156-163, American Chemical Society (January 1997)
	AT	<u>34</u>	Multhaup, G., <i>et al.</i> , "Interaction between the zinc(II) and the heparin binding site of the Alzheimer's disease β A4 amyloid precursor protein (APP)," <i>FEBS Lett.</i> 355:151-154, Elsevier Science B.V. (November 1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OTPE J.
JUL 27 2004
PATENT & TRADEMARK

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
0609.4540003/TJS/FRC
FIRST NAMED INVENTOR
Bush *et al.*
FILING DATE
October 10, 2001

APPLICATION NO.
09/972,913
ART UNIT
1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	35	Multhaup, G., <i>et al.</i> , "The Amyloid Precursor Protein of Alzheimer's Disease in the Reduction of Copper(II) to Copper(I)," <i>Science</i> 271:1406-1409, American Association for the Advancement of Science (March 1996)
	AS	35	Münch, G., <i>et al.</i> , "Advanced glycation endproducts in ageing and Alzheimer's disease," <i>Brain Res. Rev.</i> 23:134-143, Elsevier Science (February 1997)
	AT	35	Okada, H., <i>et al.</i> , "Effects of Metal-Containing Drugs Taken Simultaneously with Clotioquinol Upon Clinical Features of SMON," <i>J. Toxicol. Sci.</i> 9:327-341, Doku Say-o Kenky-ukai (1984)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>36</u>	Owen, C.A., Jr., "Uptake of ⁶⁷ Cu by Ceruloplasmin <i>In Vitro</i> (38878)," <i>Proc. Soc. Exp. Biol. Med.</i> 149:681-682, Blackwell Science (July 1975)
	AS	<u>36</u>	Padmanabhan, G., <i>et al.</i> , "Clioquinol," in <i>Analytical Profiles of Drug Substances</i> , Volume 18, Florey, K., ed., Academic Press, Inc., San Diego, CA, pp. 57-90 (1989)
	AT	<u>36</u>	Pérez, A.A., <i>et al.</i> , "Alzheimer Amyloids A β 1-40 and A β 1-42 are Differentially Degraded by Insulin Degrading Enzyme (IDE) From Human Brain," <i>Soc. Neurosci. Abstracts</i> 23:821, Society for Neuroscience (October 1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

QIPE JC
JUL 27 2004
PATENT & TRADEMARK

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>37</u>	Peters, G., and Rodgers, M.A.J., "Single-Electron Transfer from NADH Analogues to Singlet Oxygen," <i>Biochim. Biophys. Acta</i> 637:43-52, Elsevier (August 1981)
	AS	<u>37</u>	Pierce, J.E.S., <i>et al.</i> , "Immunohistochemical Characterization of Alterations in the Distribution of Amyloid Precursor Proteins and β -Amyloid Peptide after Experimental Brain Injury in the Rat," <i>J. Neurosci.</i> 16:1083-1090, Society for Neuroscience (February 1996)
	AT	<u>37</u>	Potempa, L.A., <i>et al.</i> , "Effect of Divalent Metal Ions and pH upon the Binding Reactivity of Human Serum Amyloid P Component, a C-reactive Protein Homologue, for Zymosan," <i>J. Biol. Chem.</i> 260:12142-12147, American Society for Biochemistry and Molecular Biology (October 1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>38</u>	Richardson, J.S., <i>et al.</i> , "On the Possible Role of Iron-Induced Free Radical Peroxidation in Neural Degeneration in Alzheimer's Disease," <i>Ann. N.Y. Acad. Sci.</i> 648:326-327, New York Academy of Science (1992)
	AS	<u>38</u>	Roberts, G.W., <i>et al.</i> , "βA4 amyloid protein deposition in brain after head trauma," <i>Lancet</i> 338:1422-1423, Lancet Publishing Group (December 1991)
	AT	<u>38</u>	Robinson, S.R. <i>et al.</i> , "Most amyloid plaques contain ferritin-rich cells," <i>Alzheimer's Res.</i> 1:191-196, Rapid Science Publishers (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>39</u>	Rogers, J., <i>et al.</i> , "Clinical trial of indomethacin in Alzheimer's disease," <i>Neurology</i> 43:1609-1611, Lippincott, Williams & Wilkins (August 1993)
	AS	<u>39</u>	Roher, A.E., <i>et al.</i> , "Morphology and Toxicity of A β -(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease," <i>J. Biol. Chem.</i> 271:20631-20635, American Society for Biochemistry and Molecular Biology (August 1996)
	AT	<u>39</u>	Rumble, B. <i>et al.</i> , "Amyloid A4 Protein and Its Precursor in Down's Syndrome and Alzheimer's Disease," <i>N. Engl. J. Med.</i> 320:1446-1452, Massachusetts Medical Society (June 1989)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>40</u>	Sadowski, M. <i>et al.</i> , "Astrocyte and microglia reaction in Alzheimer's disease in the hippocampal formation- a quantitative analysis," <i>Alzheimer's Res. 1</i> :71-76, Rapid Science Publishers (1995)
	AS	<u>40</u>	Sano, M., <i>et al.</i> , "A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease," <i>N.Engl. J. Med. 336</i> :1216-1222, Massachusetts Medical Society (April 1997)
	AT	<u>40</u>	Sayre, L.M., "Alzheimer's Precursor Protein and the Use of Bathocuproine for Determining Reduction of Copper(II)," <i>Science 274</i> :1933-1934, American Association for the Advancement of Science (December 1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>41</u>	Schnabel, J., "New Alzheimer's Therapy Suggested," <i>Science</i> 260:1719-1720, American Association for the Advancement of Science (June 1993)
	AS	<u>41</u>	Schubert, D., and Chevion, M., "The Role of Iron in Beta Amyloid Toxicity," <i>Biochem. Biophys. Res. Commun.</i> 216:702-707, Academic Press (November 1995)
	AT	<u>41</u>	Selkoe, D.J., "Cell Biology of the Amyloid B-protein Precursor and the Mechanism of Alzheimer's Disease," <i>Annu. Rev. Cell Biol.</i> 10:373-403, Annual Reviews (1994).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>42</u>	Seubert, P., <i>et al.</i> , "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids," <i>Nature</i> 359:325-327, Nature Pub. Co. (September 1992)
	AS	<u>42</u>	Shiraki, H., "Neuropathological aspects of the etiopathogenesis of subacute myelo-optico-neuropathy (SMON)," in <i>Handbook of Clinical Neurology. Intoxications of the Nervous System Part II</i> , Vinken, P. J. and Bruyn, G. W., eds., North-Holland Publishing Company, Amsterdam, Holland, pp.141-198 (1979)
	AT	<u>42</u>	Shivers, B.D., <i>et al.</i> , "Alzheimer's disease amyloidogenic glycoprotein: expression pattern in rat brain suggests a role in cell contact," <i>EMBO J.</i> 7:1365-1370, Oxford University Press (1988)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OIRE
 JUL 27 2004
 JC98
 PATENT & TRADEMARKS
 INFORMATION

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>43</u>	Shoji, M., <i>et al.</i> , "Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing," <i>Science</i> 258:126-129, American Association for the Advancement of Science (October 1992)
	AS	<u>43</u>	Sisodia, S.S., <i>et al.</i> , "Cellular and molecular biology of Alzheimer's disease and animal models," <i>Neuroimaging Clin. N. Am.</i> 5:59-68, W.B. Saunders Co. (February 1995)
	AT	<u>43</u>	Skinner, M., <i>et al.</i> , "Observations on the amyloid-degrading activity of serum and its relationship to human neutrophil elastase," <i>Chem. Abst.</i> 101:453, Abstract No. 101:208677n, American Chemical Society (December 1984)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>44</u>	Smalheiser, N.R., and Swanson, D.R., "Indomethacin and Alzheimer's disease," <i>Neurology</i> 46:583, Lippincott, Williams & Wilkins (February 1996)
	AS	<u>44</u>	Smith, C., <i>et al.</i> , "The molecular pathology of Alzheimer's disease: are we any closer to understanding the neurodegenerative process?," <i>Neuropathol. Appl. Neurobiol.</i> 20:322-38, Blackwell Scientific Publications (August 1994)
	AT	<u>44</u>	Smith, M.A., <i>et al.</i> , "Radical AGEing in Alzheimer's disease," <i>Trends Neurosci.</i> 18:172-176, Elsevier/North-Holland (April 1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

O I P E JC9
 JUL 27 2004
 PATENT & TRADEMARK

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>45</u>	Smith, M.A., <i>et al.</i> , "Iron accumulation in Alzheimer disease is a source of redox-generated free radicals," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 94:9866-9868, National Academy of Sciences (September 1997)
	AS	<u>45</u>	Sobue, I., "Clinical aspects of subacute myelo-optico-neuropathy (SMON)," in <i>Handbook of Clinical Neurology. Intoxications of the Nervous System Part II</i> , Vinken, P. J. and Bruyn, G. W., eds., North-Holland Publishing Company, Amsterdam, Holland, pp.115-139 (1979)
	AT	<u>45</u>	Soto, C., <i>et al.</i> , "β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy," <i>Nat. Med.</i> 4:822-826, Nature Pub. Co. (July 1998)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>46</u>	Soto, C., <i>et al.</i> , "Structural Determinants of the Alzheimer's Amyloid β -Peptide," <i>J. Neurochem.</i> 63:1191-1198, Blackwell Science (October 1994)
	AS	<u>46</u>	Stankovic, A., and Mitrovic, D.R., "Aluminum Salts Stimulate Luminol-Enhanced Chemiluminescence Production by Human Neutrophils," <i>Free Radic. Res. Comm.</i> 14:47-55, Harwood Academic Publishers (1991)
	AT	<u>46</u>	Tanzi, R.E., <i>et al.</i> , "The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene," <i>Nat. Gen.</i> 5:344-350, Nature Pub. Co. (December 1993)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>47</u>	Tanzi, R.E., <i>et al.</i> , "Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus," <i>Science</i> 235:880-884, American Association for the Advancement of Science (February 1987)
	AS	<u>47</u>	Tamura, Z., "Clinical Chemistry of Cloniquinol," <i>Jpn. J. Med. Sci. Biol.</i> 28:69-77, National Institute of Health (1975)
	AT	<u>47</u>	Tateishi, J., <i>et al.</i> , "Strain-differences in dogs for neurotoxicity of cloniquinol," <i>Lancet</i> 1:1289-1290, Lancet Publishing Group (June 1972)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>48</u>	Tateishi, J., <i>et al.</i> , "Myeloneuropathy in dogs induced by iodoxyquinoline," <i>Neurology</i> 22:702-709, Lippincott, Williams & Wilkins (July 1972)
	AS	<u>48</u>	Tateishi, J., <i>et al.</i> , "Autoradiographic Distribution of ¹³¹ I-Clioquinol in Canine and Feline," <i>Folia. Psychiatr. Neurol. Jpn.</i> 26:159-164, Japanese Society for Psychiatry and Neurology (1972)
	AT	<u>48</u>	Tateishi, J., <i>et al.</i> , "Experimental Myelo-optic Neuropathy Induced by Clioquinol," <i>Acta Neuropath. (Berl.)</i> 24:304-320, Springer Verlag (1973)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>49</u>	Tateishi, J., <i>et al.</i> , "Neurotoxicity of Clioquinol. Part III: Autoradiographic Distribution of Radioactive Clioquinol in Several Species of Animals," <i>Seishin Shinkeigaku Zasshi</i> . 75:187-196, Nihon Seishin Shinkei Gakkai (1973)
	AS	<u>49</u>	Tateishi, J., <i>et al.</i> , "Neurotoxicity of Clioquinol in Laboratory Animals," <i>Lancet</i> 2:1095, Lancet Publishing Group (November 1972)
	AT	<u>49</u>	Teller, J.K., <i>et al.</i> , "Presence of soluble amyloid β -peptide precedes amyloid plaque formation in Down's Syndrome," <i>Nature Med.</i> 2:93-95, Nature Pub. Co. (January 1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>50</u>	Terhune, M.W., and Sandstead, H.H., "Decreased RNA Polymerase Activity in Mammalian Zinc Deficiency," <i>Science</i> 177:68-69, American Association for the Advancement of Science (July 1972)
	AS	<u>50</u>	Thomas, T., <i>et al.</i> , " β -Amyloid-mediated vasoactivity and vascular endothelial damage," <i>Nature</i> 380:168-171, Nature Pub. Co. (March 1996)
	AT	<u>50</u>	Tomiyama, T., <i>et al.</i> , "Rifampicin Prevents the Aggregation and Neurotoxicity of Amyloid β Protein <i>In Vitro</i> ," <i>Biochem. Biophys. Res. Comm.</i> 204:76-83, Academic Press (October 1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>51</u>	Tomiyama, T., <i>et al.</i> , "Inhibition of Amyloid β Protein Aggregation and Neurotoxicity by Rifampicin," <i>J. Biol. Chem.</i> 271:6839-6844, American Society for Biochemistry and Molecular Biology (March 1996)
	AS	<u>51</u>	Thompson, C.M. <i>et al.</i> , "Regional Brain Trace-Element Studies in Alzheimer's Disease," <i>Neurotoxicology</i> 9:1-8, Elsevier Science (1988)
	AT	<u>51</u>	Tomski, S.J., and Murphy, R.M., "Kinetics of Aggregation of Synthetic β -Amyloid Peptide," <i>Arch. Biochem. Biophys.</i> 294:630-638, Academic Press (May 1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>52</u>	Treuhaft, P.S., and McCarty, D.J., "Synovial Fluid pH, lactate, Oxygen and Carbon Dioxide Partial Pressure in Various Joint Diseases," <i>Arthritis Rheum.</i> 14:475-484, Wiley-Liss (July-August 1971)
	AS	<u>52</u>	Van Nostrand, W.E., "Zinc (II) Selectively Enhances the Inhibition of Coagulation Factor XIa by Protease Nexin-2/Amyloid β -Protein Precursor," <i>Thromb. Res.</i> 78:43-53, Pergamon Press (April 1995)
	AT	<u>52</u>	Warren, P.J., <i>et al.</i> , "The Distribution of Copper in Human Brain," <i>Brain</i> , 83:709-717, Oxford University Press (1960)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OTPE JCS
JUL 27 2004
PATENT & TRADE

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>53</u>	Weismann, K., and Knudsen, L., "Effects of Penicillamine and Hydroxyquinoline on Absorption of Orally Ingested ⁶⁵ Zinc in the Rat," <i>J. Invest. Dermatol.</i> 71:242-244, Blackwell Science (October 1978)
	AS	<u>53</u>	Wood, S.J., <i>et al.</i> , "Physical, Morphological and Functional Differences between pH 5.8 and 7.4 Aggregates of the Alzheimer's Amyloid Peptide A β ," <i>J. Mol. Biol.</i> 256:870-877, Academic Press (March 1996)
	AT	<u>53</u>	Yates, C.M., <i>et al.</i> , "Enzyme Activities in Relation to pH and Lactate in Postmortem Brain in Alzheimer-Type and Other Dementias," <i>J. Neurochem.</i> 55:1624-1630, Blackwell Science (November 1990)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

OTPE JC84
JUL 27 2001

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>54</u>	Zagorski, M.G., and Barrow, C.J., "NMR Studies of Amyloid β -Peptides: Proton Assignments, Secondary Structure, and Mechanism of an α -Helix \rightarrow β -Sheet Conversion for a Homologous, 28-Residue, N-Terminal Fragment," <i>Biochemistry</i> 31:5621-5631, American Chemical Society (June 1992)
	AS	<u>54</u>	Beal, M.F., "Energy, Oxidative Damage, and Alzheimer's Disease: Clues to the Underlying Puzzle," <i>Neurobiol. Aging</i> 15:S171-S174, Pergamon Press (1994)
	AT	<u>54</u>	Markesbery, W.R., and Ehmann, W.D., "Brain Trace Elements in Alzheimer Disease," Chapter 22 in <i>Alzheimer Disease</i> , Terry, R.D. <i>et al.</i> , eds., Raven Press, Ltd., New York (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.

0609.4540003/TJS/FRC

APPLICATION NO.

09/972,913

FIRST NAMED INVENTOR

Bush *et al.*

FILING DATE

October 10, 2001

ART UNIT

1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	55	Soto, C., <i>et al.</i> , "Inhibition of Alzheimer's Amyloidosis by Peptides That Prevent β -Sheet Conformation," <i>Biochem. Biophys. Res. Comm.</i> 226:672-680, Academic Press (September 1996)
	AS		
	AT		

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.